{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:33:35Z","timestamp":1793716415817,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017962","name":"Jiangsu Commission of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"publisher","award":["ZD2021028"],"award-info":[{"award-number":["ZD2021028"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bcp.2025.116903","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T13:26:13Z","timestamp":1743341173000},"page":"116903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["N6-methyladenosine-modified RNF220 induces cisplatin resistance and immune escape via regulating PDE10A K48-linked ubiquitination in bladder cancer"],"prefix":"10.1016","volume":"236","author":[{"given":"Kai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9570-2891","authenticated-orcid":false,"given":"Qingyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.116903_b0005","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.bcp.2025.116903_b0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bcp.2025.116903_b0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bcp.2025.116903_b0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrurol.2017.179","article-title":"Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy","volume":"15","author":"Felsenstein","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bcp.2025.116903_b0025","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2025.116903_b0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bcp.2025.116903_b0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bcp.2025.116903_b0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2025.116903_b0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13046-023-02614-3","article-title":"HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1\/PKM2 pathway","volume":"42","author":"Lv","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116903_b0050","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.116903_b0055","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2025.116903_b0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCRESAHA.122.322264","article-title":"PDE10A inactivation prevents doxorubicin-induced cardiotoxicity and tumor growth","volume":"133","author":"Chen","year":"2023","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2025.116903_b0065","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.116903_b0070","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","article-title":"The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update","volume":"89","author":"Siddiqui","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bcp.2025.116903_b0075","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41375-020-01105-0","article-title":"Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression","volume":"35","author":"Sasi","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2025.116903_b0080","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: Much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.116903_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq4736","article-title":"RNF220 is an E3 ubiquitin ligase for AMPA receptors to regulate synaptic transmission","volume":"8","author":"Ma","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bcp.2025.116903_b0090","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41418-020-00609-7","article-title":"RNF220 mediates K63-linked polyubiquitination of STAT1 and promotes host defense","volume":"28","author":"Guo","year":"2021","journal-title":"Cell Death Differ."},{"issue":"541\u201353","key":"10.1016\/j.bcp.2025.116903_b0095","first-page":"e4","article-title":"Fine-tuning of Shh\/Gli signaling gradient by non-proteolytic ubiquitination during neural patterning","volume":"28","author":"Ma","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2025.116903_b0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/jmcb\/mjz087","article-title":"ZC4H2 stabilizes RNF220 to pattern ventral spinal cord through modulating Shh\/Gli signaling","volume":"12","author":"Ma","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2025.116903_b0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-023-44576-2","article-title":"Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma","volume":"15","author":"Dai","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.116903_b0110","article-title":"METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma","author":"Jin","year":"2024","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2025.116903_b0115","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","article-title":"Reading, writing and erasing mRNA methylation","volume":"20","author":"Zaccara","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2025.116903_b0120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13046-023-02638-9","article-title":"METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy","volume":"42","author":"Sun","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116903_b0125","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41422-018-0040-8","article-title":"Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2025.116903_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112485","article-title":"CircZNF609 inhibited bladder cancer immunotherapy sensitivity via enhancing fatty acid uptake through IGF2BP2\/CD36 pathway","volume":"137","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2025.116903_b0135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ni.2492","article-title":"The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA","volume":"14","author":"Zhang","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2025.116903_b0140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrm3394","article-title":"Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages","volume":"13","author":"Kulathu","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2025.116903_b0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","article-title":"Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation","volume":"20","author":"Huang","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2025.116903_b0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drup.2015.11.003","article-title":"Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation","volume":"24","author":"Ferreira","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bcp.2025.116903_b0155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41585-024-00857-z","article-title":"Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence","volume":"21","author":"Zhang","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bcp.2025.116903_b0160","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.7150\/thno.25130","article-title":"Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism","volume":"8","author":"Yeon","year":"2018","journal-title":"Theranostics."},{"key":"10.1016\/j.bcp.2025.116903_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100938","article-title":"Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms","volume":"68","author":"Li","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bcp.2025.116903_b0170","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/nm.3739","article-title":"Ubiquitination in disease pathogenesis and treatment","volume":"20","author":"Popovic","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2025.116903_b0175","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00280-018-3651-3","article-title":"Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation","volume":"82","author":"Ni","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2025.116903_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111706","article-title":"PR-619, a general inhibitor of deubiquitylating enzymes, diminishes cisplatin resistance in urothelial carcinoma cells through the suppression of c-Myc: an in vitro and in vivo study","volume":"22","author":"Hsu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.116903_b0185","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","article-title":"N(6)-methyladenosine modulates messenger RNA translation efficiency","volume":"161","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.116903_b0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature12730","article-title":"N6-methyladenosine-dependent regulation of messenger RNA stability","volume":"505","author":"Wang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.116903_b0195","article-title":"HDAC2-mediated METTL3 delactylation promotes DNA damage repair and chemotherapy resistance in triple-negative breast cancer","author":"He","year":"2025","journal-title":"Adv. Sci. (weinh)"},{"key":"10.1016\/j.bcp.2025.116903_b0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12943-019-1036-9","article-title":"METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner","volume":"18","author":"Han","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.116903_b0205","doi-asserted-by":"crossref","DOI":"10.1007\/s10555-024-10189-4","article-title":"The roles of PD-L1 in the various stages of tumor metastasis","author":"He","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bcp.2025.116903_b0210","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116903_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101611","article-title":"Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial","volume":"8","author":"Ferreiro-Pantin","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.bcp.2025.116903_b0220","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials","volume":"28","author":"Bellmunt","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.116903_b0225","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann. Oncol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225001650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T16:07:14Z","timestamp":1744819634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225001650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":45,"alternative-id":["S0006295225001650"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116903","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N6-methyladenosine-modified RNF220 induces cisplatin resistance and immune escape via regulating PDE10A K48-linked ubiquitination in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.116903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116903"}}